Tags

Type your tag names separated by a space and hit enter

Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol.
Psychopharmacology (Berl). 2009 Apr; 203(2):241-50.P

Abstract

RATIONALE

Preclinical evidence suggests that non-cannabinoid neurotransmitter systems are involved in the behavioral and physiological effects of cannabinoids, but relatively little research has been conducted in humans.

OBJECTIVES

The aims of this study were to assess whether oral Delta(9)-tetrahydrocannabinol (Delta(9)-THC) would function as a discriminative stimulus in humans and to examine the substitution profile of drugs acting at opioid, GABA, and dopamine systems.

METHODS

Healthy subjects who reported moderate cannabis use were enrolled. Subjects learned to identify when they received oral 25 mg Delta(9)-THC or placebo under double-blind conditions. Once subjects acquired the discrimination (i.e., > or =80% drug-appropriate responding for four consecutive sessions), multiple doses of Delta(9)-THC, the GABA(A) positive modulator triazolam, the micro-opioid agonist hydromorphone and the dopamine reuptake inhibitor methylphenidate were tested to determine if they shared discriminative-stimulus effects with the training dose of Delta(9)-THC.

RESULTS

Eight subjects (N = 8) accurately discriminated Delta(9)-THC and completed the study. The training dose of Delta(9)-THC functioned as a discriminative stimulus and produced prototypical subject-rated drug effects. All of the drugs tested produced significant effects on the self-report questionnaires, but only Delta(9)-THC substituted for the training dose.

CONCLUSION

These results suggest that the discriminative-stimulus effects of Delta(9)-THC in humans are not directly mediated through central neurotransmitter systems acted upon by the drugs tested in this study.

Authors+Show Affiliations

Department of Behavioral Science, University of Kentucky College of Medicine, College of Medicine Office Building, Lexington, KY 40536-0086, USA. jalile2@email.uky.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19018520

Citation

Lile, Joshua A., et al. "Substitution Profile of Delta9-tetrahydrocannabinol, Triazolam, Hydromorphone, and Methylphenidate in Humans Discriminating Delta9-tetrahydrocannabinol." Psychopharmacology, vol. 203, no. 2, 2009, pp. 241-50.
Lile JA, Kelly TH, Pinsky DJ, et al. Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol. Psychopharmacology (Berl). 2009;203(2):241-50.
Lile, J. A., Kelly, T. H., Pinsky, D. J., & Hays, L. R. (2009). Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol. Psychopharmacology, 203(2), 241-50. https://doi.org/10.1007/s00213-008-1393-3
Lile JA, et al. Substitution Profile of Delta9-tetrahydrocannabinol, Triazolam, Hydromorphone, and Methylphenidate in Humans Discriminating Delta9-tetrahydrocannabinol. Psychopharmacology (Berl). 2009;203(2):241-50. PubMed PMID: 19018520.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol. AU - Lile,Joshua A, AU - Kelly,Thomas H, AU - Pinsky,David J, AU - Hays,Lon R, Y1 - 2008/11/19/ PY - 2008/04/16/received PY - 2008/10/23/accepted PY - 2008/11/20/pubmed PY - 2009/10/6/medline PY - 2008/11/20/entrez SP - 241 EP - 50 JF - Psychopharmacology JO - Psychopharmacology (Berl) VL - 203 IS - 2 N2 - RATIONALE: Preclinical evidence suggests that non-cannabinoid neurotransmitter systems are involved in the behavioral and physiological effects of cannabinoids, but relatively little research has been conducted in humans. OBJECTIVES: The aims of this study were to assess whether oral Delta(9)-tetrahydrocannabinol (Delta(9)-THC) would function as a discriminative stimulus in humans and to examine the substitution profile of drugs acting at opioid, GABA, and dopamine systems. METHODS: Healthy subjects who reported moderate cannabis use were enrolled. Subjects learned to identify when they received oral 25 mg Delta(9)-THC or placebo under double-blind conditions. Once subjects acquired the discrimination (i.e., > or =80% drug-appropriate responding for four consecutive sessions), multiple doses of Delta(9)-THC, the GABA(A) positive modulator triazolam, the micro-opioid agonist hydromorphone and the dopamine reuptake inhibitor methylphenidate were tested to determine if they shared discriminative-stimulus effects with the training dose of Delta(9)-THC. RESULTS: Eight subjects (N = 8) accurately discriminated Delta(9)-THC and completed the study. The training dose of Delta(9)-THC functioned as a discriminative stimulus and produced prototypical subject-rated drug effects. All of the drugs tested produced significant effects on the self-report questionnaires, but only Delta(9)-THC substituted for the training dose. CONCLUSION: These results suggest that the discriminative-stimulus effects of Delta(9)-THC in humans are not directly mediated through central neurotransmitter systems acted upon by the drugs tested in this study. SN - 1432-2072 UR - https://www.unboundmedicine.com/medline/citation/19018520/Substitution_profile_of_Delta9_tetrahydrocannabinol_triazolam_hydromorphone_and_methylphenidate_in_humans_discriminating_Delta9_tetrahydrocannabinol_ L2 - https://dx.doi.org/10.1007/s00213-008-1393-3 DB - PRIME DP - Unbound Medicine ER -